IRL 752

Drug Profile

IRL 752

Alternative Names: IRL752

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Integrative Research Laboratories
  • Class Antidementias; Small molecules
  • Mechanism of Action Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dementia
  • Phase I Attention-deficit hyperactivity disorder

Most Recent Events

  • 05 Oct 2017 IRLAB receives approval from the Finnish MPA for a phase II trial in Finland
  • 04 Oct 2017 Phase-II clinical trials in Dementia in Scandinavia
  • 29 Feb 2016 Swedish Medical Products Agency (MPA) and the Regional Ethical Review Board, Uppsala, approve initiation of phase I trials for IRL 752 in Attention-deficit hyperactivity disorder and Dementia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top